Top Stories
The drugmaker has expanded an alliance with Eversana to bring AI-powered workflows across is US commercial organisation.
Sentivera, founded by Population Health Partners and ARCH Venture Partners, will have ex-China rights to an inflammatory disease candidate developed by Haisco.
Jazz's bispecific antibody could challenge Keytruda-based regimens after extending overall survival in Phase III.
Following a review, BMS concluded that the Cellares-partnered Cell Shuttle system could not meet the necessary requirements to make commercial Breyanzi.
The dual-action eye drop combines 5% lifitegrast, the active ingredient in Xiidra, and perfluorohexyloctane, the active ingredient in Miebo, into a single twice-daily treatment.
Conference News
Roche's deal with Hanmi Pharma adds some validation to an up-and-coming novel target in obesity, potentially getting in ahead of the field's heavy hitters as the bandwagon builds for urocortin-2 (UCN2).
BOSTON, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living ...
SAN DIEGO--(BUSINESS WIRE)-- Endeavor BioMedicines ("Endeavor"), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patient...
SURPASS-IPF is the first industry-sponsored Phase 3 head-to-head trial in idiopathic pulmonary fibrosis (IPF) and will evaluate the potential superiority of deupirfenidone 825 mg TID vs. pirfenidone 8...
First Immunotherapy-Based Regimen to Show Statistically Significant and Clinically Meaningful PFS Benefit in a Global Phase III Study of EGFR-Mutated NSCLC after Third-Generation EGFR TKI ProgressionU...
